Abstract | CONTEXT: OBJECTIVES: In this report we examined the association of both drugs with congenital malformations using data from the International Clearinghouse for Birth Defects Surveillance and Research. DESIGN: The study used a case-affected control analysis and included 18,131 cases with malformations and reported first-trimester exposure to medication. A total of 127 subjects were born to mothers with known first-trimester antithyroid drug exposure. RESULTS: CONCLUSIONS: Further studies are required to exhaustively evaluate the associations between propylthiouracil and birth defects because of the low number, the lack of biological plausibility, and the possibility of underdiagnosis. Association between methimazole/ carbimazole exposure and omphalocele and choanal atresia is consistent with previous reports and definitely suggests that these malformations could be part of a specific, even if rare, embryopathy.
|
Authors | Maurizio Clementi, Elena Di Gianantonio, Matteo Cassina, Emanuele Leoncini, Lorenzo D Botto, Pierpaolo Mastroiacovo, SAFE-Med Study Group |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 95
Issue 11
Pg. E337-41
(Nov 2010)
ISSN: 1945-7197 [Electronic] United States |
PMID | 20668039
(Publication Type: Journal Article)
|
Chemical References |
- Antithyroid Agents
- Methimazole
- Propylthiouracil
- Carbimazole
|
Topics |
- Abnormalities, Drug-Induced
(epidemiology, etiology)
- Antithyroid Agents
(adverse effects, therapeutic use)
- Carbimazole
(adverse effects, therapeutic use)
- Case-Control Studies
- Female
- Humans
- Hyperthyroidism
(drug therapy)
- Incidence
- Methimazole
(adverse effects, therapeutic use)
- Odds Ratio
- Pregnancy
- Pregnancy Complications
(drug therapy)
- Propylthiouracil
(adverse effects, therapeutic use)
|